M2R
0.003
50%
CNJ
0.02
-73.7%
RAD
0.026
44.4%
NAE
0.002
-33.3%
MEM
0.004
33.3%
SPX
0.002
-33.3%
VKA
0.009
28.6%
RKB
0.003
-25%
RDN
0.005
25%
TAR
0.018
-25%
DRO
2.83
23%
OEL
0.004
-20%
NFM
0.017
21.4%
TDO
0.14
-17.6%
4DX
2.95
20.9%
BMO
0.033
-15.4%
VAR
0.006
20%
AX8
0.006
-14.3%
PTX
0.11
18.3%
BNL
0.006
-14.3%
BLU
0.007
16.7%
ECS
0.006
-14.3%
GLL
0.007
16.7%
ENV
0.006
-14.3%
MGL
0.245
16.7%
SER
0.006
-14.3%
VSR
0.035
16.7%
AZY
0.537
-13.4%
EOS
7.44
15.2%
ALM
0.007
-12.5%
BKB
0.8
15.1%
MML
0.028
-12.5%
SNX
0.031
14.8%
PL9
0.007
-12.5%
HPG
1.385
14.5%
SRJ
0.014
-12.5%
CLX
2.15
13.2%
GG1
0.185
-11.9%
MQR
0.009
12.5%
D3E
0.305
-11.6%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Interviews

Alpha HPA (ASX:A4N) is an Australian specialty materials company supplying high-purity aluminium materials used in semiconductors, EV batteries, AI data centres and advanced manufacturing. With Stage 2 of its HPA First Project progressing in Gladstone, Queensland, Alpha is developing what is expected to become the world’s largest single-site high-purity aluminium facility. The company’s low-carbon refining technology is helping meet growing global demand tied to the AI and clean energy transitions. Alpha HPA Managing Director, Rob Williamson, joins Lel Smits from The Stock Network to discuss Australia’s growing role in critical minerals, advanced manufacturing and the next phase of growth for Alpha HPA. 1. Powering AI, semiconductors and EV supply chains Alpha HPA’s materials are increasingly being used across semiconductors, AI infrastructure and EV battery technologies. How is rising demand for AI data centres, advanced chips and battery safety shaping the opportunity for Alpha’s proprietary technology? 2. Building Australia’s role in future manufacturing With Stage 2 progressing in Gladstone, Alpha is developing what is expected to become the world’s largest single-site high-purity aluminium facility. How important is this project in strengthening Australia’s position in critical minerals and advanced manufacturing? 3. Scaling production and commercial momentum Alpha recently completed a $225 million capital raising while expanding customer qualification programs across semiconductors and battery materials. What key milestones should investors watch as Alpha scales production and expands into global technology supply chains? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
Alpha HPA (ASX:A4N): Powering AI, EVs and advanced manufacturing with Australian innovation
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS43OEQ1OTk4ODU2N0E5RUYz

Alpha HPA (ASX:A4N): Powering AI, EVs and advanced manufacturing with Australian innovation

Pengana Private Equity Trust (ASX:PE1) offers investors access to global private equity and private credit through a listed ASX structure. Managed with Grosvenor Capital Management, PE1 targets diversified institutional-quality investments across healthcare, hospitality and global growth sectors. William Dougall, Investment Specialist at Pengana Capital Group, discusses recent portfolio additions and how PE1 balances long-term opportunities with short-term currency impacts. 1. Market backdrop 2025 was a huge year for private markets, with US deal value exceeding $1 trillion for the second time in private equity history. What are you seeing out there now, and how is it shaping the way you're positioning PE1? 2. Performance and portfolio quality What's been working well in the PE1 portfolio over the last 12 months, and how does that compare to what listed markets have delivered? 3. Top 10 holdings What are some of the standout companies in PE1's top 10, and is there one that doesn't get much attention but probably should? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
Pengana Private Equity Trust (ASX:PE1): Private equity across pharmaceuticals & hospitality
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS44Q0Q0NjMwREMzREQ1RkE4

Pengana Private Equity Trust (ASX:PE1): Private equity across pharmaceuticals & hospitality

Epiminder (ASX:EPI), a medical device company developing continuous brain monitoring technology for epilepsy, has reached 25 patient enrolments in its DETECT US clinical study. DETECT is a prospective, randomised, controlled study supporting reimbursement for the Minder® System. Around 20 leading US sites are now active, including Mayo Clinic, Harvard, Stanford, Yale, Duke and the University of Pennsylvania, with enrolment accelerating as activation expands. CEO Rohan Hoare joins Lel Smits from The Stock Network to discuss what this patient enrolment milestone signals for trial execution, how site expansion is translating into recruitment, and the next key inflection points for investors. 1. Site expansion translating into enrolment growth The study has reached 25 enrolled patients across more than 19 US sites, with recruitment accelerating alongside ongoing site activation. What is driving this momentum, and how should investors interpret early enrolment as an indicator of execution strength? Take 2 start 2. Scaling toward critical trial thresholds The study targets 210 patients across up to 25 US sites, with the next milestone of 50 patients expected in mid Q3 CY2026. How critical are the coming enrolment phases in validating clinical execution at scale? 3. Epiminder signal quality featured in publication Epiminder was recently featured in another publication, can you talk us through the highlights? 4. Epiminder Director alignment With four Epiminder Directors recently increasing their shareholdings in the company, what does this signal about internal confidence in the DETECT study progress and Epiminder's longer-term clinical and commercial outlook? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
Epiminder (ASX:EPI): DETECT Study reaches 25th enrolment as US trial momentum builds
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS4zNjNFN0I4ODYzQTQ3QTg2

Epiminder (ASX:EPI): DETECT Study reaches 25th enrolment as US trial momentum builds

Acrux (ASX:ACR) has expanded its partnership with Gedeon Richter Plc, enabling the Australian launch of transdermal Estradiol spray Lenzetto®. The amended agreement could deliver up to $5.4 million in milestone payments tied to regulatory and sales targets over two years. Lenzetto®, developed using Acrux’s Patchless Patch™ technology, is already sold in more than 40 countries as a hormone replacement therapy treatment for menopausal symptoms linked to oestrogen deficiency. Its Australian entry also comes amid ongoing shortages of Menopause Hormone Therapy (MHT) products. CEO John Warmbrunn joins Lel Smits from The Stock Network to discuss the financial significance of the deal, the opportunity in women’s health, and how Lenzetto® strengthens Acrux’s long-term strategy. 1. Financial impact of the Lenzetto® expansion The amended agreement could deliver Acrux up to $5.4 million in milestone payments. How important is this deal financially, and what does it say about the value of Acrux’s IP and partnerships? 2. Addressing Australia’s MHT shortage Lenzetto® is expected to help ease shortages of menopause hormone therapy products in Australia. Why is this launch timely, and how could it improve treatment access for women? 3. Expanding Acrux’s women’s health strategy Lenzetto® is already commercialised in more than 40 countries. How does the Australian expansion support Acrux’s broader women’s health ambitions and future product pipeline? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
Acrux (ASX:ACR): Lenzetto® Australia deal unlocks $5.4M milestone pathway & addresses MHT shortage
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS44Q0M3MkM5NzExMTIyRDg3

Acrux (ASX:ACR): Lenzetto® Australia deal unlocks $5.4M milestone pathway & addresses MHT shortage

Teaminvest Private Group (ASX:TIP) has entered into a binding term sheet to acquire the Intelligent Investor business, including management rights to its four Intelligent Investor Exchange Traded Funds, from InvestSMART Group (ASX:INV). The proposed acquisition would significantly expand TIP’s retail distribution capability while aligning with the group’s long-standing value investing philosophy and research-driven approach. Intelligent Investor would become TIP’s primary direct-to-consumer retail brand, complementing its existing wholesale, institutional and funds management operations. Teaminvest Private Group Chief Executive Officer, Andrew Coleman, joins Lel Smits from The Stock Network to discuss the strategic rationale behind the proposed acquisition, the future of the Intelligent Investor brand and TIP’s long-term growth strategy. 1. Strategic rationale behind the acquisition TIP has built a strong reputation across wholesale investing, education and funds management. Why was Intelligent Investor the right strategic fit for the group, and how does the proposed acquisition strengthen TIP’s long-term growth strategy? 2. Expanding retail distribution and scale Intelligent Investor brings more than 272,000 active subscribers, four ASX-listed ETFs and a highly recognised value investing brand. How important is this acquisition in accelerating TIP’s retail distribution capability and expanding the group’s research ecosystem? 3. Building the future of Intelligent Investor TIP has said Intelligent Investor will become its primary retail-facing brand while maintaining its distinct identity and value investing philosophy. What opportunities do you see to grow the platform and deepen engagement with Australian investors over the long term? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
Teaminvest Private Group (ASX:TIP): Expanding retail reach through Intelligent Investor acquisition
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS5EQTkxMkVFODRENEJBMERF

Teaminvest Private Group (ASX:TIP): Expanding retail reach through Intelligent Investor acquisition

Green360 Technologies (ASX:GT3), through Suvo Minerals Australia, has secured a major commercial milestone with a non-binding MOU signed with Holcim (Australia) Pty Ltd, part of global building materials leader Holcim Group. The agreement marks Eco-Clay’s first named commercial customer following initial production at Calix’s Bacchus Marsh facility. Up to 4,800 tonnes per annum will be supplied into Holcim’s Victorian operations, with a binding supply agreement targeted within 90 days. Green360 Executive Chairman Aaron Banks joins The Stock Network’s Lel Smits to discuss commercial momentum, scale-up, and market validation. 1. First commercial customer validation What does securing Holcim as your first named Eco-Clay customer signal for product validation and broader market acceptance? 2. Scaling from pilot to commercial supply With first production already achieved and supply now moving toward 4,800 tonnes per annum, how quickly can Eco-Clay transition from early validation to meaningful commercial scale? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
Green360 Technologies (ASX:GT3): Holcim MOU unlocks first commercial Eco-Clay supply
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS4zODMyNzgxRTc3QzBBMjJE

Green360 Technologies (ASX:GT3): Holcim MOU unlocks first commercial Eco-Clay supply

European Lithium (ASX:EUR) has surged on the back of a proposed merger with NASDAQ-listed Critical Metals Corp (CRML), positioning the company as a global critical minerals player across lithium and rare earths. Under the non-binding deal, EUR shareholders would receive Critical Metals Corp shares and own ~45% of the combined entity. Joining The Stock Network’s Lel Smits, Executive Chairman Tony Sage explains how the transaction could accelerate growth and global relevance. 1. Critical minerals merger rationale You’ve announced a proposed merger with Critical Metals Corp. How does this deal strengthen your position in critical minerals and why is now the right time to scale globally? 2. Strategic assets in lithium and rare earths With exposure to Wolfsberg in Austria and Tanbreez in Greenland, how important are these assets in securing supply for Western markets? 3. Critical minerals demand Demand for lithium and rare earths is accelerating. Where do you see the biggest supply gaps emerging over the next 3–5 years? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
European Lithium (ASX:EUR, FRA:PF8, OTC:EULIF): Deal with NASDAQ-listed Critical Metals Corp (CRML)
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS40Mzg1NEVCNkVCNjNGNDk0

European Lithium (ASX:EUR, FRA:PF8, OTC:EULIF): Deal with NASDAQ-listed Critical Metals Corp (CRML)

Epiminder (ASX:EPI) is a medical device company developing next-generation technology for continuous brain monitoring in epilepsy patients. The Company is advancing its DETECT study in the United States, a large-scale clinical trial designed to support future reimbursement for its Minder® device. Momentum is building, with 18 leading US medical centres now contracted and patient enrolment ramping quickly, positioning the study for significant expansion this year. Epiminder CEO Rohan Hoare joins Lel Smits from The Stock Network to discuss what this progress means, how the study is tracking against key milestones, and Epiminder's plans as it scales. 1. DETECT study momentum We’ve seen a strong ramp-up in the DETECT study, with 18 US medical centres now contracted and patient enrolment increasing. What’s driving this acceleration and how should investors interpret this progress? 2. Path to scale and key milestones You’re targeting 210 patients across up to 25 leading US sites. How important are the next few months in terms of hitting enrolment milestones? 3. Commercial pathway and funding position With a strong cash balance of $83.8 million and funding through to 2028, how does this position Epiminder to execute on DETECT, complete G1 development, and move towards commercial rollout? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
Epiminder (ASX:EPI): DETECT study momentum accelerates, scaling towards US approval
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS44OEYxMzRDRDg1REM4QjIw

Epiminder (ASX:EPI): DETECT study momentum accelerates, scaling towards US approval

Tetratherix (ASX:TTX) is integrating regenerative medicine with advanced health AI, data science and digital infrastructure through its Tetramatrix™ platform. As multiple products progress through clinical validation and regulatory pathways, Tetratherix is also building a scalable AI-driven data platform to accelerate discovery, improve decision-making and support commercial growth. Vice President of Digital Science, Andrew (AJ) Fisher joined Tetratherix to lead its Digital Science pillar and is a senior technology leader with 25+ years’ experience across AI, data platforms, Internet of Things (IoT) and digital transformation. AJ. joins The Stock Network’s Lel Smits to discuss how artificial intelligence in healthcare and connected data systems are reshaping how Tetratherix is developing and scaling its products. 1. Building a health AI platform in regenerative medicine How is your background in AI, data science and digital strategy helping to build a health AI platform at Tetratherix, and in simple terms, how does this improve how new medical treatments are discovered and developed? 2. Connecting data across lab, manufacturing and real-world healthcare You’re designing a connected healthcare data ecosystem that links experiments, production and external data. How does this kind of end-to-end data integration in healthcare help accelerate product development and enable scalable commercialisation? 3. Creating a compounding AI-driven data advantage You’ve spoken about building a compounding data asset powered by AI. How does this approach to machine learning in healthcare create a long-term competitive advantage and position Tetratherix as a scalable digital health platform? _ _ _ Subscribe to TSN's YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1 _ _ _ Follow TSN for the latest stock news and interviews: Twitter: https://twitter.com/thestocknet Instagram: https://www.instagram.com/thestocknetwork/ LinkedIn: https://www.linkedin.com/company/the-stock-network/ TikTok: https://www.tiktok.com/@thestocknet?lang=en Facebook: https://www.facebook.com/TheStockNet/ _ _ _ Connect with our host Lel Smits online - @LelSmits - Twitter / X: https://twitter.com/lelsmits - Instagram: https://www.instagram.com/lelsmits/ - LinkedIn: https://www.linkedin.com/in/leldesmits/ - TikTok: https://www.tiktok.com/@lelsmits?lang=en - Facebook: https://m.facebook.com/lelsmits/ - Threads: https://www.threads.net/@lelsmits _ _ _ Disclaimer The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss. This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer. _ _ _ Visit TSN's website to sign up for regular stock updates: www.thestocknetwork.com.au _ _ _
Tetratherix (ASX:TTX): The tools to leverage health AI & data to scale regenerative medicine
YouTube Video UExTblZqZ2VlMkp1ZTZJZFNvOHpPVlZYMVpkWUNwdXctVS5EMzdGRjBBQzVCNEY2NDhG

Tetratherix (ASX:TTX): The tools to leverage health AI & data to scale regenerative medicine

View More

Get the latest ASX stock market news delivered to your inbox

By proceeding, you can confirm you understand that we handle personal informational in accordance with our Privacy Policy